Genmab shares rise 4% on J&J cancer drug FDA approval

Genmab shares rose about 4% after the FDA approved a cancer drug developed by Johnson & Johnson, with the headline indicating the approval as the catalyst. The transmission mechanism here is company-specific rather than macro: approval of a partnered oncology asset typically affects the partner's revenue outlook, milestone and royalty expectations, and the perceived de-risking of its pipeline, which is why the move is concentrated in Genmab's equity rather than broader indices. Exposure is therefore most direct for Genmab shareholders and for biotech and oncology-focused funds that hold the stock, while spillover to the wider healthcare sector or to Johnson & Johnson's own share price is likely modest given the size of its diversified portfolio. Traders should watch the formal label details and any commercial launch commentary from J&J on the first earnings call following approval, since indication scope and pricing guidance determine how much of the approval value flows through to Genmab's expected royalty stream.

HIGH-impact news is typically a market-moving event with multi-pip or multi-percent intraday reactions. Examples include central bank rate decisions, major CPI/NFP releases, geopolitical shocks, mega-cap earnings beats/misses, and regulatory announcements. Traders typically position-reduce or hedge ahead of scheduled HIGH-impact events, and follow the wire in real time to react to unscheduled ones (war headlines, central-bank emergency statements, surprise corporate actions). The Trading News Terminal squawk box reads every HIGH-impact headline aloud the moment it hits the wire — so active traders don't have to stare at the feed.

Active traders typically follow a three-step workflow when a market-moving headline hits the wire: (1) read the headline on the terminal or hear it on the squawk box; (2) assess whether the news is already priced in (by checking intraday price action in the seconds before) or whether it's genuinely new information; (3) act — either entering a breakout position, fading an overreaction, or tightening stops on existing trades. Trading News Terminal's Pro plan delivers wire-grade headlines within seconds of the source, with automatic audio squawk on every HIGH-impact event, so the read-assess-act cycle never waits on a refresh button.